Effects of sustained release of statin by means of tricalcium phosphate lysine delivery system in defect and segmental femoral injuries on certain biochemical markers in vivo

Biomedical Sciences Instrumentation

Volumn 42, Issue , 2006, Pages 126-135

  Adah, Felix ^a   Benghuzzi, Hamed ^a   Tucci, Michelle ^a   Russell, George ^a   England, Barry ^b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Biochemical markers; Drug Delivery System; Fracture; Healing; Osteogenic agent; Simvastatin; Statins; Tricalcium Phosphate Lysine

Indexed keywords

BIOCHEMISTRY; BONE; CHOLESTEROL; DATA ACQUISITION; ENZYME KINETICS; HORMONES;

HEALING; OSTEOGENIC AGENT; SIMVASTATIN; STATINS; TRICALCIUM PHOSPHATE LYSINE;

ENZYME INHIBITION;

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; CALCIUM PHOSPHATE CERAMIC; CHOLESTEROL; FOLLITROPIN; GLUTATHIONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LUTEINIZING HORMONE; LYSINE DERIVATIVE; MALONALDEHYDE; PROTEIN; SIMVASTATIN; TESTOSTERONE; TRICALCIUM PHOSPHATE LYSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BONE DEFECT; BONE DEVELOPMENT; BONE INJURY; BONE STRENGTH; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG IMPLANT; FEMUR; FRACTURE HEALING; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LONG TERM CARE; MALE; MORPHOMETRICS; NONHUMAN; RAT; SHORT COURSE THERAPY; SUSTAINED DRUG RELEASE;

ANIMALS; BIOLOGICAL MARKERS; CALCIUM PHOSPHATES; DRUG CARRIERS; FEMORAL FRACTURES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LYSINE; MALE; PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN; TREATMENT OUTCOME;

EID: 33745202291     PISSN: 00678856     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (48)

1. Delbose, S, Cristol JP, Mimran, A, and Jover B. Simvastain attenuates cardiovascular effects and oxidative stress induced by Angiotensin II. Arch Mal Coeru Vaiss, 2001;94 (11): 1199-1202.
2. Bouletreau, PJ, Warren, SM, and Longaker, MT. The molecular biology of distraction osteogenesis. J Craniomaxillofac Surg. 2002;30(1):1-11.
3. Peter, CP, Cook, WO, Numamaker, DM, Provost, MT, Seedor, JG, and Rodan, GA. Effects of alendronate on fracture healing and bone remodeling in dog. Journal of Orthopaedic Research. 1996;14(1): 74-79.
4. Mundy, G, Garrett, R, Harris, S, Chan, J, Chen, G, Rossini, G, Boyce, B, Zhao, M, and Gutierrez, G. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286:946-1949.
5. Ohnaka, K, Shimoda, S, Nawata, H, Shimokawa, H, Kaibuchi K, Iwamoto, Y, and Takayanagi, R. Pitavastatin enchanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun. 2001;287(2):337-342.
6. Garrett, R, and Mundy, GR. The role of statins as potential targets for bone formation. Arthritis Res. 2002;4 (4):237-240.
7. Staal, A, Frith, JC, French, MH, Swartz, J, Gungor, T, Harrity, TW, Tamasi, J, Rogers, and Feyen, JH. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res. 2003;18(1):88-96.
8. Edwards, CJ, and Spector, TD, (2002). Statins and modulators of bone formation. Arthritis Res. 2002;4(3):151-153.
9. Sica, DA, and Gehr, TW. Rhabdomyolysis and statin therapy: Relevance to the elderly. Am J Geriatr Cardiol. 2002;1(1):48-55.
10. Corsini, A Bellosta, S, Baetta, R, Fumagalli, R, Paoletti, R, and Bernini, F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 2000;84 (3):413-428.
11. Bauer, DC, Mundy, GR, Jamal, SA, Black, DM, Cauley, JA, Insrud, KE, van der Klift, M, and Pols, HA. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Inter Med. 2004;164(2):146-152.
12. Meier, CR, Schlienger, RG, Kraenzlin, ME, Schlegel, B, and Jick, H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 2000;283(24): 3205-3210.
13. Wang, PS, Solomon, DH, Mogun, H, and Avorn, J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients.(comment). JAMA. 2000;283(24): 3211-3216.
14. Chan, KA, Andrad, SE, Boles, M, Buist, DSM, Chase, GA, Donahue, JG, Goddman, MJ, Gurwitz, JH, LaCroix, AZ, and Platt, R. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. The Lancet. 2002;355(9222): 2185-2188.
15. Edwards, CJ, Hart, DJ, and Spector, TD. Oral stains and increased bone-mineral density in post-menopausal women. Lancet. 2000;355 (9222): 2218-2219.
16. Reid, IR, Hague, W, Emberson, J, Baker, J, Tonkin, A, Hunt, D, MacMahon, S, and Sharpe, N. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long term intervention with pravastatin in ischaemic disease. Lancet. 2001;357(9255):509- 512.
17. Van Staal, TP, Wegman, S, de Varies, F, Leufkens, B, and Cooper, C. Use of statins and risk of fractures. JAMA. 2001;285:1850-1855.
18. Oxlund, H, Dalstra, M, and Andressen, TT. Statin given perorally to adult rats increases cancellous bone mass and compressive strength. Calcified Tissue International. 2001;69(5):299-304.
19. Travia, D, Tosi, F, Negri, C, Faccini, G, Moghetti, P, and Muggeo, M. Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads. J Clin Endocrinol Metab. 1995;80(3): 836-840.
20. Santini, SA, Carozza, C, Luli, P, Zuppi, C, Caro, TG, and Musumeci, S. Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia. J Atheroscler Thromb. 2003;10(3): 160-164.
21. Purvis, K, Tollefsrud, A, Rui, H, Haug, E, Norseth, J, Viksmoen, L, and Lund, H. Short-term effects of treatment with simvastatin on testicular function in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Pharmacol. 1992;42(1):61-64.
22. Benghuzzi, H. The effect of sustained delivery of androstendion on the functional activities of adult male rats. Biomedical Sciences Instrumentation. 1998;34:7-12.
23. Benghuzzi, HA, and England, BG. The effect of sustained delivery of danazol and antioxidants on lipoprotein profiles of adult female mice. Biomedical Sciences Instrumentation. 1995;31:171-176.
24. Cavett, W, Tucci, M, Cason, Z, Lemos, L, and England, B. Cellular responses to various levels of sustained delivery of testosterone in the ventral prostate. Biomedical Sciences Instrumentation. 1997;33: 155-160.
25. Varnado, M, Tucci, M, Cason, Z, Mohamed, A, and Benghuzzi, H. Germinal cell alterations associated with sustained delivery of testosterone enanthate in adult male rats. Biomedical Sciences Intrumentation. 1997;33:161-165.
26. Nagy, EA, and Bajpai, PK. Development of a ceramic matrix system for continuous delivery of azidothymidine. Biomedical Sciences Instrumentation. 1994;30:181-186.
27. England, BG, Benghuzzi, HA, Possley, RM, and Bajpai, PK. The effect of various testosterone concentrations released from ceramic delivery systems on the circulating hormone levels of adult castrated rams. Biomedical Sciences Instrumentation. 1991;27:89-195.
28. Benghuzzi, HA, England, BG, and Bajpai, PK. Tricalcium phosphate amino acid capsules as a drug delivery system for steroid hormones. Biomedical Sciences Instrumentation. 1991;27:197-203.
29. Benghuzzi, HA, Barbaro, RM, and Bajpai, PK. In vitro release of azidothymidine (AZT) by ceramic drug delivery. Biomedical Sciences Instrumentation. 1990;26:151-156.
30. Benghuzzi, HA, Possley, R, and England, BG. Pulsatile delivery of progesterone and estradiol to mimic the ovulatory surge in adult cwes by means of TCPL implants. Biomedical Sciences Instrumentation. 1994;30:187-196.
31. Conflitti, J, Graves, M, Russell, G, Tucci, M, and Benghuzzi, H. Plating of rat femoral shaft osteotomics: Report of a technique and preliminary results. Biomedical Sciences Instrumentation. 2003;39:278-283.
32. Nixon, A, Benghuzzi, H, and Cason, Z. Morphometric evaluation of ovarian tissue exposed to PCB conventionally and in a sustained manner. Biomedical Sciences Instrumentation. 2003;(39): 434-439.
33. Benghuzzi, H, Tucci, Eckie, R, and Hughes, J. The effects of sustained delivery of diosgenin on the adrenal gland of female rats. Biomedical Sciences Instrumentation. 2003;39: 335-340.
34. Gordon, E, Lasserre, A, Stull, P, Bajpai, PK. A zinc based self-setting ceramic bone substitute for local delivery of testosterone. Biomedical Sciences Instrumentation. 1997;33: 131-136.
35. Thylin, MR, McConnell, JC, Schmid, MJ, Reckling, RR, Ojha, J, Bhattacharyya, I, Marx, DB, and Reinhardt, RA. Effects of simvastatin gels on murine calvarial bone. Journal of Periodontology. 2002;73(10):1141-1148.
36. Skoglund, B, Forslund, C, and Aspenberg, P. Simvastatin improves fracture healing in mice. J Bone Miner Res.; 2002;(11): 2004-2008.
37. Guliaeva, NV, and Levshina, IP. Characteristics of free-radical oxidation and antiradical protection of the brain in adaptatin to chronic Stress. Biull Eksp Biol Med. 1988;106(8):153-156.
38. Koida, M, Fukuyama, R, and Nakamuta, H, Osteoporosis requires bone-specific statins. Current Pharmaceutical Design. 2004;10(21):2605-2618.
39. Adah, F, Benghuzzi, H, Tucci, M, Russell, G, Tsao, A, Olivier, J, England, B. Evaluation pf the male reproductive organs after treatment with continuous sustained delivery of statin for fracture healing. Biomedical Sciences Instrumentation, 2005;41:54-61.
40. Stein, EA, Farnier, M, Waldstreicher, J, and Mercuri, M. Effects of statins on biomarkers of bone metabolism: A randomised trial. Nutrition Metabolism & Cardiovascular Diseases, 200;11(2):84-87.
41. Kawaguchi, H, Nakamura, K, TAbata, Y, Ikada, Y, Aoyama, I, Anzai, J, Nakamura, T, Hiyama, Y, and Tamura, M. Acceleration of fracture healing in nonhuman rimates by fibroblast growth factor-2. Journal of Clinical Endocrinology and metabolism, 2001;86 (2): 875-880.
42. Travia, D, Tosi, F, Negri, C, Faceini, G, Moghetti, P, and Muggeo, M. Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads. J Clin Endocrino Metab, 1995;80 (3): 836-840
43. Bernini, GP, Argenio, GF, Gasperi, Vivaldi, MS, Franchi, F, Salvetti, A. Effects of long-term simvastatin treatment on testicular and adrenal steroidogenesis in hypercholesterolemic patients. Endocrinol Invest., 1994;17 (4):227-233.
44. Kano, K, Nishikura, K, Yamada, y, and Arisaka, O. Effect of fluvastatin dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria. Clin Nephrol., 2003;60(2):85-9.
45. Buemi, M, Allegra, A, Crica, F, Aloisi C, Giacobbe, M, Pettinato G, Corsonello A, Senatore M, and Frisina N. Effect of fluvastain on proteinuria in patients with immunoglobulin a nephropathy. Clin Pharmacol Ther., 2000;67 (4): 427-431.
46. Wassmann, S, Laufs, U, Muller, K, Konkol, C, Ahlbory, K, Baumer, AT, Linz, W, Bohn, M, and Nickenig, G. Cellular antioxidant effects of atorvastatin in viteo and in vivo. Arterioscler Thromb Vasc Biol., 2002;22(2):300-305.
47. von Knoch, F, Heckelei, A, Wedemeyer, C, Saxter, G, Hilken, G, Henschke, F, Loer, F, and Knoch, M. The effect of simvastatin on polyethylene-induced osteolysis. Biomaterials, 2005;26(17):3549-3555.
48. Oxlund, H, and Andreassen, TT. Simvastatin treatment partially prevents overiectomy-induced bone loss while increasing cortical bone formation. Bone, 2004;34(4):609-618.